Show: Training Data · Publisher: Sequoia Capital · Host: Sonya Huang, Pat Grady
Episode URL: https://pscrb.fm/rss/p/traffic.megaphone.fm/CPUAI6181193044.mp3?updated=1744664492
Publish date: 2025-04-15
Duration: NAs
Default source credibility: HIGH — Sequoia partners interview frontier-lab founders + F500 AI buyers. VC-hosted — portfolio-company framing on recommendations; named guest metrics stay HIGH. Peer-tier to No Priors in quality.
- ARC Institute’s Patrick Hsu discusses the convergence of AI and biology, emphasizing the potential for predictive models to revolutionize drug discovery and development.
- The development of EVO2, a biological foundation model, showcases advancements in interpreting and generating genomic sequences, potentially transforming our understanding of genetic mutations and their effects.
- The integration of AI in biology extends beyond drug design, aiming to create a comprehensive understanding of biological systems at all scales, from molecules to ecosystems.
Extracted quotes
| # | Credibility | Speaker | Org | Timestamp | Topic | Quote |
|---|---|---|---|---|---|---|
| 1 | HIGH | Patrick Hsu (Co-founder) | ARC Institute | 50:00 | 01-ai-native-landscape | We can design full IgG antibodies, right? Not single chain binders like nanobodies, but just the real antibody medicines that, you know, we kind of know and love today. We can just design their CDR regions. They’re going to bind really well. You can one shot it and you can kind of do point and click on that, you know, that surface of your enzyme. I can just bind it, right? One shot. |
| 2 | HIGH | Patrick Hsu (Co-founder) | ARC Institute | 50:03 | 01-ai-native-landscape | I think the thing that will mature over the next couple of years is that we can actually design enzymes de novo. I think that will be really interesting and also lots of efforts. And again, this is all in the world of proteins. And I think one of the things that most people who think about this stuff are very protein coded. And so a lot of our work is to sort of zoom out from proteins and think about cells. |
Per-quote detail
1. Patrick Hsu — ARC Institute (50:00)
We can design full IgG antibodies, right? Not single chain binders like nanobodies, but just the real antibody medicines that, you know, we kind of know and love today. We can just design their CDR regions. They’re going to bind really well. You can one shot it and you can kind of do point and click on that, you know, that surface of your enzyme. I can just bind it, right? One shot.
- Credibility: HIGH — Specific claim about antibody design capabilities, unscripted interview.
- Topic tag:
01-ai-native-landscape
2. Patrick Hsu — ARC Institute (50:03)
I think the thing that will mature over the next couple of years is that we can actually design enzymes de novo. I think that will be really interesting and also lots of efforts. And again, this is all in the world of proteins. And I think one of the things that most people who think about this stuff are very protein coded. And so a lot of our work is to sort of zoom out from proteins and think about cells.
- Credibility: HIGH — Specific claim about enzyme design capabilities, unscripted interview.
- Topic tag:
01-ai-native-landscape
Extracted 2026-04-14T20:30:58 via scripts/podcast_mine.py (MLX mlx-community/Qwen2.5-32B-Instruct-4bit).